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Summary 
T cells from an HLA-DRll/DR12 responder were stimulated in mixed lymphocyte culture with 
cells carrying the DR1 antigen. After priming, T cells proliferated in response to both DR1- 
positive-stimulating cells and a peptide derived from a polymorphic region of the HLA-DRBI*0101 
chain presented by responder's antigen-presenting cells (APC). The dominant epitope recognized 
by the primed T cells corresponded to residue 21-42 and was presented by the responder's HLA- 
DR12  antigen.  The DR1 peptide-reactive T  cells express T  cell receptor  V33.  The results 
demonstrate that  allopeptides  derived from the processing  and presentation  of donor major 
histocompatibility complex molecules by host-derived APC trigger alloreactivity. The frequency 
of T cells engaged in the indirect pathway of allorecognition is about 100-fold lower than that 
of T cells participating in the direct recognition of native HLA-DR antigen. However, indirect 
allorecognition may play an important role in chronic allograft rejection,  a phenomenon that 
is mediated by the activation  of T  helper cells and of alloantibody-producing B cells. 
T 
wo pathways of antigen recognition have been consid- 
ered in T cell responses to MHC alloantigens (1-4). A 
direct pathway involves T cells capable of recognizing alloan- 
tigens as intact molecules on the surface of allogeneic stimu- 
lator cells. The TCRs recognize, in this case, unknown pep- 
tides bound in the groove of allogeneic  MHC molecules and/or 
adjacent  epitopes  of the aUogeneic MHC  molecule.  The 
precursor frequency of T cells involved in the direct recogni- 
tion pathway is extremely high, with estimates  of 1-5% 
of T  cells exhibiting blastogenic  responses  to  allogeneic- 
stimulating cells in MLC (2). There is ample evidence that 
the direct pathway of allorecognition is the principal  con- 
tributor to antigraft cytotoxic T cell responses mediating early 
rejection episodes. The very high number of precursor T cells 
participating in direct aUorecognition has been attributed to 
molecular mimicry resulting from the engagement of TCRs 
whose innate reactivity was for a complex formed by a self- 
MHC molecule with an endogenous or exogenous peptide 
(5-9). 
The indirect pathways of allorecognition has come into 
focus more recently, with the realization that this pathway 
may explain T helper cell-dependent cytotoxic T cell and al- 
loantibody responses (10-13). In this pathway, T cells recog- 
nize graft MHC alloantigens  that have been processed and 
presented by host APC. Indirect recognition is restricted by 
the host MHC class II molecule, which has bound a peptide 
derived from the processing of an allogeneic MHC molecule 
that is, therefore,  the classical pathway of conventional  an- 
tigen recognition by CD4 T cells (10-16). The involvement 
of alloantigen-specific CD4 T helper cells, as mediators  of 
alloantibody generation, suggests that the indirect pathway 
plays an essential role in chronic rejection, e.g., in the steady 
but continuous attrition (2-5%/yr) of organ allografts late 
after transplantation  (17, 18). 
In previous studies we have shown that synthetic peptides 
derived from the amino acid sequence of the DR31"0101 chain 
stimulate  the reactivity of T  cells from allogeneic (DR11) 
and syngeneic (DR1) responders  (13). 
The aim of this study was to establish the relative contri- 
bution to alloreactivity of the direct and indirect pathways 
of T cell recognition of an allogeneic MHC class II mole- 
cule. T cells from an HLA-DR11/12 responder were primed 
in MLC with allogeneic DRl-positive cells and then tested 
for reactivity to DR1 stimulators and to synthetic DR1 pep- 
tides in the presence of responder's  APC. We now report 
that T cells involved in indirect recognition are 100-fold less 
frequent than T cells participating in the direct recognition 
pathway, and that the dominant epitope that they recognize 
in the context of DR31"1201 lies within residue 21-42  of 
the DR31 chain. 
Materials and Methods 
HLA Typing.  The HLA class II genotype of all PBMC selected 
for these experiments was characterized  by conventional serology 
and by genomic typing of in vitro amplified DNA with sequence- 
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primers and SSOP provided by the XI International Histocompati- 
bility Workshop  (19). 
Peptide Synthesis.  Peptides  were synthesized with an automated 
peptide synthesizer (430A; Applied Biosystems, Inc., Foster City, 
CA), using modified Merrifield chemistry, as previously described 
(13, 20, 21). Seven partially overlapping peptides, corresponding 
to residues 1-20, 11-30, 21-42, 31-50, 43-62, 51-70, and 66-90, 
were synthesized. 
Limiting Dilution Analysis.  Responding cells were obtained from 
the peripheral blood of a healthy male (LS) with the HLA-DRll, 
DQ3/DR12, DQ3 genotype.  PBMC at l@/ml were stimulated 
in 24-well plates (Costar Corp.,  Cambridge,  MA) with an equal 
number of irradiated (3,000 rad) PBMC from an individual (EC) 
whose genotype is DR1, DQ1/DR3, DQ2, in ILPMI 1640 sup- 
plemented with 10% pooled human  serum, 2 mM t-glutamine, 
and 50/~g/ml gentamicen (Gibco Laboratories, Grand Island, NY) 
11 d after MLC stimulation T cells were tested in an limiting dilu- 
tion  assay (LDA), 1 e.g.,  at  concentrations  of 2  x  104  to  50 
cells/weU for reactivity  to:  (a) irradiated  autologous  (LS) APC 
(5 x  104  PBMC/well);  (b)  irradiated  allogeneic PBMC  (5  x 
104/well) from a DR1, DQ1 homozygous  stimulator;  (c) irradi- 
ated allogeneic PBMC from an individual homozygous for DR2, 
DQ1, e.g., matching the stimulator for DQ1; (d) autologous APC 
(5  x  104/well) plus a cocktail of seven different synthetic 20-mer 
peptides spanning the first domain of DRBI*0101; and (e) irradi- 
ated  L  cells transfected  with  HLA-DR1  (Xhh  International 
Histocompatibility Workshop). All cultures were fed after 3 d with 
fresh medium containing rlL-2 (5 U/ml). On day 6, cultures were 
labeled with [3H]TdR and harvested after 18 h. The precursor fre- 
quency of reactive T cells was calculated as described (13, 20). 
Establishment of Allopeptide-Specific T Cell Line and Clones.  T 
cells from individual LS, which were stimulated for 11 d in I~ 
with irradiated PBMC from EC,  were primed  in 24-well plates 
at  106/ml with 10/~g/ml each of the seven HLA-DR1 peptides 
in culture medium. 3 d after stimulation rib2 (Boehringer Mann- 
heim Biochemicals, Indianapolis, IN) was added at 5 U/ml. The 
cultures were fed every 3 to 4 days with medium containing rlL-2 
at 20 U/ml.  After  14 d,  T cells (2  x  106/ml) were stimulated 
with the peptide mixture  and irradiated autologous PBMC (2  x 
106/ml) in medium containing 20 U/ml of rlL-2. The culture was 
restimulated two more times, at 14-d interval, under identical con- 
ditions. The resulting T cell line (TCL), named TCbLS-anti-EC, 
was tested for reactivity to each of the seven peptides. This TCL 
was cloned by limiting  dilution  at 0.5 cells/well in medium con- 
taining DR.1 peptides, irradiated autologous  APC, and rlL-2, T 
cell clones (TCC) were expanded by restimulation  with peptide 
and autologous  APC. 
Proliferation Studies.  Responding  T cells (2  x  104/well) were 
cocuhured  with  5  x  104 irradiated  APC  in  round-bottomed 
microcuhure  plates (Costar  Corp.).  DR1 peptides at 2.5/~g/ml 
and/or stimulating  cells (5  x  104/cuhure) were added to the cul- 
tures.  After  48 h of incubation  the cultures  were labeled with 
[3H]thymidine and then  harvested after an additional  18 h. 
Antibody Blocking Assay.  mAbs were added to the cultures at 
the initiation of the blastogenesis assay. L243 and W6/32 (Amer- 
ican Type Culture Collection,  Rockville, MD) were used as cell 
culture supernatants. Anti-DP,  -DQ, -CD4 and -CD8 antibodies 
1  Abbreviations used in this ~per: LDA, limiting dilution analysis; TCC, 
T cell clones; TCL, T cell lines. 
(Becton Dickinson  & Co.,  Mountain  View, CA) were dialyzed 
against medium  and used at 1 #g/ml. 
Determination of TCR-V~ usage by PCR.  cDNA was prepared 
from total RNA by reverse transcription  and amplified by PCR 
using V/~ and C~ primers as previously described (13, 21). The 
amplified products  were separated on 2%  agarose gel.  1 /~g of 
HaeIII-digested ck x 174 DNA (GIBCO BRL, Gaithersburg, MD) 
was run  in parallel as molecular weight markers. 
Results 
LDA ofT Cells Participating in Direct and Indirect Allorecog- 
nition.  We first tried to determine what is the relative con- 
tribution of direct and indirect recognition to an MLC re- 
sponse. For this, we primed T  cells, in a primary MLC, to 
allogeneic DKl-positive cells and we measured in an LDA 
the frequency of cells responding to DKl-positive-stimulating 
cells and to synthetic DR.1 peptides. Because the stimulating 
cells  also expressed the possible target  structures DQ, DP, 
and DR3, to discriminate between the response to DR1 and 
the response to the other MHC class II antigens,  we used 
as stimulator cells that are homozygous for DR1, DQ1 and 
for DR2, DQ1.  In addition,  we used as stimulator L cells 
transfected only with DR1. The frequency of cells responding 
directly to DR1, DQ1 homozygous cells was 1:328 and that 
of cells reacting  to the DR1 L  cell transfectant  was  1:361 
(Table 1). The frequency of cells involved in the direct recog- 
nition of DQ1, as expressed by DR2, DQ1 homozygous cells, 
was 1:1,529. The l~  T cells showed no reac- 
tivity to DR1 peptides when tested in cultures without APC. 
However, when irradiated,  autologous APC and the DR1 
peptide mixture were added together, proliferation was ob- 
served. The estimated frequency of T cells capable of recog- 
nizing DR1 peptide(s) bound to an autologous MHC class 
II molecule was 1:43,992 (Table  1). Thus,  the frequency of 
cells engaged in the indirect pathway of recognition is '~ 100- 
fold lower than that of cells engaged in direct recognition. 
Proliferative Response of TCL to DRI Peptides.  The LDA 
results  showed that  T  cells recognizing  in context of self- 
MHC the processed allogeneic DR1 molecule, which was 
shed or secreted by aUostimulating cells, were activated during 
I~  To determine the structure of the dominant epitope 
of the DR1 molecule that  these cells recognized,  we chal- 
lenged them individually with each of the seven  (partially 
overlapping) synthetic peptides derived from the amino acid 
sequence of the DI~1"0101  molecule. 
Blastogenic responses occurred only when the DR1 pep- 
tide 21-42 was added to the cultures (Fig.  1). None of the 
other synthetic DR1 peptides restimulated the cells in the 
presence of the responder's APC. Hence, peptide 21-42 com- 
prises the dominant  epitope of the DR.1 molecule. 
MHC Restriction Studies.  Having determined that the DR1 
peptide 21-42 comprises the dominant DR1 epitope recog- 
nized by TCL-LS-anti-EC, we next tried to identify the MHC 
restriction element. For this, TCL-LS-anti-EC and the TCC 
derived from it were tested for reactivity to peptide 21-42 
in the presence of APC sharing with LS either the DI~1"1101 
or DRBl*1201 allele.  The responses of the TCL and of six 
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HLA-DR, DO  Reactive 
Stimulating cells  phenotype  cells 
Allogeneic PBMC  (NN) 
Allogeneic PBMC  (NS) 
L cell transfectants 
Autologous PBMC (LS)  + 
DR1 peptides 
Autologous PBMC (LS) 
DR1,  DQ1  1:328 
DR2,  DQ1  1:1,529 
DR1  1:361 
DR11,  DQ3/  1:43,992 
DR12,  DQ3 
0 
PBMC from responder LS were stimulated in 11-d MLC with irradiated 
PBMC from a DR1,DRl-positive  donor. The MLC-primed T cells were 
tested in LDA for reactivity to DRl-positive  cells and DR1 peptide. 
representative clones are shown in Table 2. The line and the 
clones reacted to peptide 21-42 when DR1201-positive cells 
but  not DRl101-positive cells were used as APC.  The re- 
strictive element used by the TCL and TCC for the recogni- 
tion of DR1 peptide 21-42 is,  therefore, the DR1201 mole- 
cule.  mAbs  specific for HLA-DR  and  CD4  inhibited  the 
response of the TCL and TCC to peptide 21-42 presented 
by autologous  APC  (Fig.  2).  There  was  no inhibition  of 
proliferative responses by mAhs to HLA-class I,  DQ,  and 
DP, indicating that an HLA-DR molecule was solely respon- 
sible  for the presentation  of DR1  peptide  21-42. 
Recognition of Native DR1 Molecule by DRI Peptide-specific 
TCC.  Native DR1 molecules, expressed on DKl-positive 
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Figure  1.  DeterminationofdominantepitopeofDRlmolecule.  TCL- 
LS-anti-EC (2  x  104 cells/well) was tested for reactivity to DR1 pep- 
tides corresponding to residues 1-20, 11-30, 21-42, 31-50, 43-62, 51-70, 
and 66-90 (2.5/~g/ml)  in the presence of autologous APC (5  x  104 
cells/culture). 
APC from other individuals carrying the DR~1"1201 allele 
were added to the cultures (Table 3).  In the absence of such 
APC, the native DR1 molecule failed to stimulate, indicating 
that processing of the DR1 molecule and binding of the DR1 
peptide corresponding to the dominant epitope to the DR1201 
molecule are required for recognition to occur. We next ex- 
plored  the possibility that  cells  from individuals  heterozy- 
gous for DR1 and DR1201 would display a similar complex 
on their surface. However, stimulating cells from an individual 
(NV) carrying both the restrictive element, DR12, and the 
Table  2.  MHC Restriction of Peptide Recognition 
[3H]TdR incorporation 
DRB1  TCL  TCC 1.1  TCC 10.1  TCC 30.1  TCC 30.3  TCC 30.6  TCC 30.7 
genotype 
Cell  of APC  -  +  Peptide  -  +  Peptide  -  +  Peptide  -  +  Peptide  -  +  Peptide  -  +  Peptide  -  +  Peptide 
LS  1101/1201  129  50,752  83  30,270  1,356  54,929  111  55,883  1,180  51,017  1,437  42,330  230  32,845 
PR  1101/07  64  81  45  43  110  163  52  50  48  55  87  23  36  33 
NM  1104/0101  83  42  52  40  235  177  51  42  43  45  110  107  42  45 
NV  1201/0101  353  50,867  271  28,366  1,148  51,664  596  56,461  529  43,455  964  41,254  367  34,157 
RA  1201/1601  29  49,070  57  23,705  608  43,684  90  49,564  743  34,550  270  36,124  59  29,734 
RB  1201/0408 1,388  50,317  2,311  38,186  14,409  52,579  2,546  46,257  2,377  37,159  9,385  37,330  2,059  37,027 
RN  1501/07  112  71  60  35  357  99  54  44  113  52  162  79  49  40 
FL  0301/1601  103  121  69  57  346  561  57  73  107  96  238  158  45  63 
EC  0301/0101  131  83  70  37  219  199  50  59  160  61  107  82  37  30 
TCL LS-anti-EC and TCC (2  x  104/we11) were tested for reactivity to DR1 peptide 21-42 (2.5/~g/ml)  in the presence of APC (5  x  104/well) 
carrying different DR alleles. 
Reactions were set up in triplicates. SD is <10%. 
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Figure 2.  Effect  ofmAbs on the proliferative  response  of  TCL-LS-anti- 
EC to the DR1 peptide 21-42. TCL-LS-anti-EC (2 x 104 cells/well) was 
cultured with autologous APC (5  x  104) and DR1 peptide 21-42 (2.5 
#g/ml). mAbs were added at the initiation of the proliferative assay. 
stimulatory molecule,  DR1,  elicited activation  only when 
exogenous,  synthetic peptide 21-42 was added to the cul- 
tures (Table 2). In cultures without exogenous peptide there 
was no reactivity, suggesting that the amount of DR1 pep- 
tide 21-42 presented by the DR12 molecule expressed by this 
stimulator  was insufficient to trigger  activation. 
Molecular Mimicry of  DRI2-DRI Peptide Complexes by DR4 
Allelic  Products.  When PBMC expressing different MHC 
alleles  were used for ascertaining  the MHC-restrictive ele- 
ment required for TCC activation, an important and consis- 
tent exception was noted: cells from an individual carrying 
the  DR4  allele,  DIL81*0408,  stimulated  the  clones  even 
without the addition of exogeneous DR1 peptide. In view 
of this observation we tested our entire panel of DR4 vari- 
ants for their ability to stimulate the TCL and TCC. Cells 
expressing DRBl*0401, 0403, and 0404 elicited strong reac- 
tivity.  Cells carrying  the DR4 alleles,  DR~1"0405,  0406, 
0407, and 0408, had little stimulatory activity, while 0402- 
positive cells were not stimulator),  (Table 4). Hence, TCC 
that recognize (indirectly) DR1 peptide 21-42 presented by 
the DR1201 molecule can also recognize directly products 
of certain DR4 alleles plus unknown peptides(s). The latter 
probably present  a determinant  with  structural  homology 
to the DR1201-DR1 peptide complex. This finding supports 
the notion that molecular mimicry accounts at least in part 
for direct recognition  of allogeneic MHC molecules (9). 
TCR-VB Gene Usage.  In previous studies we have shown 
that TCL that recognize the DR1 peptide 21-42 in context 
ofa self-MHC molecule, such as DRBl*1101 and DRBI*0101, 
have a limited TCR-V3 gene usage (13, 21). In these studies, 
however, the TCL were generated by priming PBMC with 
the synthetic peptide. To establish whether indirect recogni- 
tion of DR1 peptide,  derived from the natural  processing 
of native DR1 molecule, is also the function of a restricted 
number of TCR-V3 families, we analyzed the TCR-V3 genes 
expressed by TCL-LS-anti-EC and by the clones derived from 
it. The TCL and all the six TCC that were analyzed expressed 
V33 (Fig. 3). This result is consistent with our previous finding 
that the TCR-V3 gene usage, in alloreactive TCC involved 
in indirect  recognition,  is biased. 
Discussion 
Central to the problem of allograft rejection is the under- 
standing of the molecular events resulting in allostimulation. 
The possibilities that the TCRs of some aUoreactive cells bind 
directly to the allogeneic MHC molecule with or without 
a bound peptide,  while other TCRs are engaged by com- 
plexes formed by self-MHC with peptides derived from an 
allogeneic  MHC  molecule,  have  been  both  substantiated 
(1-16). 
Table  3.  Recognition of Naturally Processed DR1 Molecule by TCL and TCC 
HLA-D1L81 genotype of 
(irradiated)  PBMC  [3H]TdK Incorporation 
Stimulator  APC  TCL  1.1  10.1  30.1  30.3  30.6  30.7 
mean cpm 
EC  0101/0301  LS 1101/1201  4,424  3,246  3,509  4,065  5,004  3,890  3,479 
EC  0101/0301  RA 1201/1601  4,118  3,869  4,376  4,453  4,260  3,602  3,255 
EC  0101/0301  RV 1501/07  237  210  300  262  135  235  322 
MN  0101/1104  LS 1101/1201  6,014  3,105  4,002  4,380  4,410  3,435  2,946 
FL  0301/1601  LS 1101/1201  209  339  144  204  279  303  311 
RV  1501/07  LS 1101/1201  359  267  144  263  237  355  254 
TCL-LS-anti-EC and TCC (2 x  104/well)  were stimulated with irradiated DRl-positive and -negative (control) PBMC (5 x  104/we11)  in the presence 
of autologous (LS) and hemiallogeneic APC (5  x  104/we11). Cultures were labeled after 48 h and harvested 18 h later. 
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[3H]TdK incorporation 
DtLS1  TCL  TCC 1.1  TCC 30.1  TCC 30.3  TCC 30.6  TCC 30.6  TCC 30.7 
genotype 
of APC  -  +  Peptide  -  +  Peptide  -  +  Peptide  -  +  Peptide -  +  Peptide  -  +  Peptide  -  +  Peptide 
mea~ r 
PM  0401/1501 4,491  2,505  8,299  7,907 23,596  24,088  4,859  3,724  8,093  7,408 19,649  17,439  4,977  3,989 
SS  0402/1502  157  329  45  41  454  192  71  37  78  62  133  154  47  45 
LD  0403/0101  15,588  11,342  8,105  6,401 32,374  21,231 14,750  10,607  12,870  10,993  25,497  22,174  9,780  7,637 
SD  0404/0301  16,269  17,360  14,331  17,687  33,742  33,873 15,672  17,264  18,502  18,977  25,503  26,581  13,887  12,488 
DY  0405/1201 1,639  51,410  1,055 28,305  11,809  42,299  2,542 40,394  3,024 37,437  6,336 33,345  1,718 32,553 
ON  0406/1402  2,173  931  2,010  963  11,646  5,987  5,791  2,003  2,851  1,429  8,780  5,095  2,118  1,545 
MN  0407/1402  636  687  1,242  420  5,399  3,993  1,393  276  1,534  705  1,910  2,312  1,123  601 
RB  -0408/1201  1,398  50,317  2,311 38,186  11,469  52,579  2,546 46,217  2,377 37,159  9,385 37,330  2,059 37,027 
TCL and TCC (2  x  104/well) were tested for reactivity to irradiated PBMC (5  x  104/weU) from individuals heterozygous for different HLA- 
DR-4 alleles in the presence or absence of DR1 peptide 21-42. 
The direct recognition pathway accounts most likely for 
the vigorous immune response elicited by allogeneic tissue 
and organs early after transplantation (10, 12). This early reac- 
tion may result in acute rejection, which can be suppressed 
by timely and vigorous therapy with steroids, OKT3, and/or 
increased dosage of immunosuppressants.  Donor dendritic 
cells are suspected to be the major source of MHC class II 
antigens that stimulate T  helper reactivity and subsequently 
contribute  to the  activation  of cytotoxic CD8  effectors. 
For most organ allograft systems the major threat to long- 
Figure  3.  Amplification of cDNA  from 
TCL-LS-anti-EC and TCC 1.1. KNAs from 
TCL (A) and TCC (B) were  reverse tramcribed, 
PCK amplified, and subjected to electropho- 
resis on 2% agarose gel. 1 #g HaelI-digested 
x 174 DNA was run in parallel as molecular 
weight markers. term survival remains chronic rejection, a slow and insidious 
process that often takes years for completion (17, 18). Chronic 
rejection has been associated with the production of lym- 
phokines and cytokines damaging the intima of the vessels 
and inducing the proliferation and differentiation of alloan- 
tibody-producing B cells (17, 18). Because the alloantibodies 
formed during chronic rejection react with donor cells and 
often exhibit antidonor MHC specificity, this process is likely 
to be mediated by T helper ceils recognizing MHC peptides 
derived from the donor MHC molecules and bound to host 
MHC molecules (13). Donor alloantigens,  which are found 
in recipient sera, may be released into the circulation from 
the injured graft or may be shed or secreted by donor den- 
dritic cells (17, 18). These soluble MHC molecules may pro- 
vide antigens for indirect allorecognition. Recent evidence 
from our and other laboratories has documented that MHC 
peptides derived from one MHC molecule can be presented 
to T cells by another MHC molecule (11-14, 22, 23). Both 
self- and allo-peptides  bind to MHC class II molecules and 
elicit oligoclonal T  cell proliferation (13, 21). Specific im- 
munosuppressive therapy should, therefore, involve blockade 
of TCR,s and/or of MHC binding sites. 
The demonstration of T cell reactivity against exogenous 
MHC peptides bound to an MHC molecule, in our previous 
studies, was based on experiments in which T cells were sen- 
sitized to HLA-DR,1 in vitro using autologous APC and syn- 
thetic DR,1 peptides (13, 20, 21). The resulting TCC reacted 
to allogeneic DR.l-positive ceils only in the presence of au- 
tologous APC. When the DR,1 molecule was coexpressed 
on the membrane of the same cell with the responder's HLA- 
DR,-restrictive  element (DR,31*ll01), the TCC was speci- 
fically stimulated, indicating that it recognized processed DR'I 
presented by  the DR,11 molecule. Residue 21-42  of the 
DR,31*0101 chain was shown to comprise the T cell deter- 
minant region eliciting T cell reactivity against the stimulating 
DR.l-positive cells. 
Although the use of a panel of synthetic peptides for in 
vitro immunization permits the identification of T cell de- 
terminant regions, this approach leaves open the criticism that 
the sensitizing peptide may not be produced during the nat- 
ural processing of the respective antigen by APC (24). Since 
indirect recognition is expected to evolve from direct recog- 
nition, which causes the release of alloantigen from injured 
donor cells and its processing and presentation by host APC, 
it was important to determine whether indeed the two events 
occur together during allostimulation. 
We approached this problem in an in vitro system by sen- 
sitizing the responder's T cells in MLC with allogeneic DR,I- 
positive cells. The MLC-primed T cells were then tested for 
direct recognition ability, i.e., for non-MHC-restricted reac- 
tivity to allogeneic DILl cells and for indirect recognition, 
i.e., for MHC-restricted recognition of synthetic DR,1 pep- 
tides. We found that the frequency of cells recognizing directly 
the alloantigen was ~100-fold higher than that of cells recog- 
nizing a DR,1 peptide presented by autologous APC. The 
dominant epitope of DR,1 recognized by the responding T 
cells in context of DR31*1201 lies within residue 21-42. 
Of particular interest was the finding that TCC specific 
for this DR'I peptide were also triggered to proliferate strongly 
by cells expressing  certain polymorphic variants  of DR4 
(DR~1"0401, 0403, and 0404). Other variants of DR4, such 
as DR,31"0402, failed to induce proliferation. This result is 
reminiscent of our previous finding that cells heterozygous 
for HLA-DR3 and -2 stimulate the reactivity ofa TCC specific 
for  the DR,1  peptide 21-42  presented in  context  of the 
responder's DRBI*0101 allele (21). In both of these cases there 
seems to be molecular mimicry between complexes formed 
by an HLA-DR, molecule, such as DR,1 or DR,12 in the present 
study, with DR,1 peptide 21-42 on one hand, and complexes 
involving an unrelated allogeneic HLA-DR molecule with 
its bound peptide on the other hand. In an attempt to ex- 
plain this crossreactivity  we examined the published amino 
acid sequence of DR,4 allelic variants  (25).  The location of 
amino acids in the first and second aUelic hypervariable  re- 
gion, corresponding to the floor of the antigen binding groove, 
is identical in all DRBI"04  alleles with the exception of 
DR,~1"0406, which has serine instead of tyrosine in posi- 
tion 37. The major difference between the various DR'31"04 
alleles occurs in the third hypervariable region, which con- 
tains the T cell contact residues. These differences, however, 
do not permit grouping of the DR4 antigens in stimulatory 
and nonstimulatory categories, corresponding to the T cell 
reactivity pattern observed in the present study. 
Since T cells capable of direct recognition recognize a bi- 
nary complex of foreign MHC and a bound peptide, the cross- 
reactivity of DR,1 peptide 21-42 presented by DR,12  and 
DR,31"04 alleles is caused most likely by the conformation 
of this complex. 
Our  observation that molecular mimicry occurs when 
MHC peptides bind as processed fragments to an HLA-DR, 
antigen for recognition by T cells has important clinical im- 
plication. First, it is possible that such complexes trigger au- 
toimmune reactions,  as has been previously suggested (26). 
Second, it is possible that sensitization to one alloantigen rec- 
ognized by T  cells in a primary graft leads to second set 
rejection of a subsequent graft carrying a different HLA pheno- 
type. This hypothesis may explain  at least in part the sig- 
nificantly lower survival of secondary grafts compared with 
primary grafts. 
The contribution of the indirect pathway of allorecogni- 
tion to aUoimmunity has been documented in animal models 
(11, 12). Benichou et al. (12) showed that after immuniza- 
tion of mice with allogeneic spleen cells or skin grafts,  the 
in vivo primed T cells proliferate in vitro in response to pep- 
tides corresponding to polymorphic regions of the allogeneic 
MHC class II molecul~ Similarly, Fangmann et al. (11) demon- 
strated that rats immunized with allopeptides showed acceler- 
ated rejection of skin allografts carrying the MHC molecule 
whose sequence was used for allopeptide synthesis. Our data 
represent the first demonstration in humans that in vitro im- 
munization with native HLA-DR, molecule, expressed on 
the surface of allogeneic cells, leads to the generation of T 
cells that react with processed forms of the alloantigen. The 
frequency of such T cells increases from ~1:250,000 in un- 
1648  Direct and Indirect Allorecognition primed population  (13) to  1:40,000 after stimulation  with 
~logeneic cells expressing the DR1 molecule. This reinforces 
the view that indirect recognition can play an important role 
in  aUograft rejection. 
Finally, consistent with our previous finding of a limited 
and biased TCR-VB gene usage in aUopeptide-specific T cells, 
in the present study we found that the DR1 peptide-specific 
TCL and the TCC derived from a DR12-positive responder 
exclusively used V~83. This finding supports the concept that 
TCR-targetted immunosuppressive therapy may be useful for 
suppression of indirect T cell alloreactivity and consequently 
of chronic  allograft rejection. 
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